– Completed $25 Million Strategic Financing; Extending Cash Runway into 2023 – Accelerated Development of AL102 Desmoid Tumor Program into Phase 2/3 Pivotal Trial –
– Completed $25 Million Strategic Financing; Extending Cash Runway into 2023 – Accelerated Development of AL102 Desmoid Tumor Program into Phase 2/3 Pivotal Trial –